The editor's roundtable: the JUPITER trial--initial results and clinical implications

Am J Cardiol. 2009 May 15;103(10):1417-25. doi: 10.1016/j.amjcard.2009.02.023.

Authors

Paul M Ridker¹, Vincent E Friedewald, Michael H Davidson, James T Willerson, William C Roberts

Affiliation

¹ Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

PMID: 19427439
DOI: 10.1016/j.amjcard.2009.02.023

No abstract available

Publication types

Clinical Conference
Research Support, Non-U.S. Gov't

MeSH terms

Aged
C-Reactive Protein / metabolism
Cardiovascular Diseases / blood
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / blood
Female
Fluorobenzenes / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Inflammation
Male
Middle Aged
Multicenter Studies as Topic
Patient Selection
Primary Prevention
Pyrimidines / therapeutic use*
Randomized Controlled Trials as Topic
Risk Assessment
Risk Reduction Behavior
Rosuvastatin Calcium
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Cholesterol, LDL
Fluorobenzenes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pyrimidines
Sulfonamides
Rosuvastatin Calcium
C-Reactive Protein